BridgeBio Oncology Therapeutics Net Tangible Assets

BridgeBio Oncology Therapeutics (BBOT) currently reports a net tangible assets of $320M as of June 2026. That compares with $-7.3M in the prior-year period — up 4543.2% year over year. Use the charts on this page to explore BridgeBio Oncology Therapeutics's net tangible assets history and peer comparisons.

BridgeBio Oncology Therapeutics's net tangible assets increased from $-7.3M to $320M — a 4543.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BridgeBio Oncology Therapeutics reported $320M in net tangible assets as of June 2026. That compares with $-7.3M in the prior-year period — up 4543.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $320M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BridgeBio Oncology Therapeutics, and consider following BBOT for alerts when major investors trade the stock.